You have full text access to this Open Access content

EMBO Molecular Medicine

Cover image for Vol. 5 Issue 8

August 2013

Volume 5, Issue 8

Pages 1147–1295

  1. Closeups

    1. Top of page
    2. Closeups
    3. Perspectives
    4. Review
    5. Research Articles
    6. Masthead
    1. You have full text access to this OnlineOpen article
      A radical opposition in body weight control (pages 1147–1148)

      Michael Ristow and Christian Wolfrum

      Article first published online: 5 AUG 2013 | DOI: 10.1002/emmm.201303094

    2. You have full text access to this OnlineOpen article
  2. Perspectives

    1. Top of page
    2. Closeups
    3. Perspectives
    4. Review
    5. Research Articles
    6. Masthead
    1. You have full text access to this OnlineOpen article
  3. Review

    1. Top of page
    2. Closeups
    3. Perspectives
    4. Review
    5. Research Articles
    6. Masthead
    1. You have full text access to this OnlineOpen article
      Hacking cell differentiation: transcriptional rerouting in reprogramming, lineage infidelity and metaplasia (pages 1154–1164)

      Gonçalo Regalo and Achim Leutz

      Article first published online: 4 JUL 2013 | DOI: 10.1002/emmm.201302834

      Thumbnail image of graphical abstract

      This review discusses cell reprogramming, epithelial metaplasia and hematopoietic lineage ambiguity, and highlights changes in cell fate that occur during tumor initiation leading to discrepancies between tumors phenotype and their cellular origin.

  4. Research Articles

    1. Top of page
    2. Closeups
    3. Perspectives
    4. Review
    5. Research Articles
    6. Masthead
    1. You have full text access to this OnlineOpen article
      Deficiency of NPGPx, an oxidative stress sensor, leads to obesity in mice and human (pages 1165–1179)

      Yi-Cheng Chang, Yu-Hsiang Yu, Jin-Yuh Shew, Wei-Jei Lee, Juey-Jen Hwang, Yen-Hui Chen, Yet-Ran Chen, Pei-Chi Wei, Lee-Ming Chuang and Wen-Hwa Lee

      Article first published online: 4 JUL 2013 | DOI: 10.1002/emmm.201302679

      Thumbnail image of graphical abstract

      Deficiency of the glutathione peroxidase NPGPx increases ROS levels in preadipocytes and promotes adipocyte differentiation via increasing oxidative stress and consequent increased fat mass and adipocyte hypertrophy.

    2. You have full text access to this OnlineOpen article
      Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers (pages 1180–1195)

      Anouk Emadali, Sophie Rousseaux, Juliana Bruder-Costa, Claire Rome, Samuel Duley, Sieme Hamaidia, Patricia Betton, Alexandra Debernardi, Dominique Leroux, Benoit Bernay, Sylvie Kieffer-Jaquinod, Florence Combes, Elena Ferri, Charles E. McKenna, Carlo Petosa, Christophe Bruley, Jérôme Garin, Myriam Ferro, Rémy Gressin, Mary B. Callanan and Saadi Khochbin

      Article first published online: 4 JUL 2013 | DOI: 10.1002/emmm.201202034

      Thumbnail image of graphical abstract

      The nuclear factor CYCLON is a new MYC cooperating factor that drives tumor growth and Rituximab resistance in lymphoma. This resistance mechanism can be targeted by next-generation epigenetic therapy by BET bromodomain inhibition downstream of MYC.

    3. You have full text access to this OnlineOpen article
      The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance (pages 1196–1212)

      Florian A. Siebzehnrubl, Daniel J. Silver, Bugra Tugertimur, Loic P. Deleyrolle, Dorit Siebzehnrubl, Matthew R. Sarkisian, Kelly G. Devers, Antony T. Yachnis, Marius D. Kupper, Daniel Neal, Nancy H. Nabilsi, Michael P. Kladde, Oleg Suslov, Simone Brabletz, Thomas Brabletz, Brent A. Reynolds and Dennis A. Steindler

      Article first published online: 1 JUL 2013 | DOI: 10.1002/emmm.201302827

      Thumbnail image of graphical abstract

      Glioblastoma have a poor prognosis, mainly due to infiltrating and therapy resistant cells leading to cancer recurrence. Here, tumor formation, invasion and resistance are not independent but intertwined processes regulated by the EMT activator ZEB1.

    4. You have full text access to this OnlineOpen article
      IgA EGFR antibodies mediate tumour killing in vivo (pages 1213–1226)

      Peter Boross, Stefan Lohse, Maaike Nederend, Johannes Hendrik Marco Jansen, Geert van Tetering, Michael Dechant, Matthias Peipp, Louise Royle, Li Phing Liew, Louis Boon, Nico van Rooijen, Wim K. Bleeker, Paul W. H. I. Parren, Jan G. J. van de Winkel, Thomas Valerius and Jeanette H. W. Leusen

      Article first published online: 5 AUG 2013 | DOI: 10.1002/emmm.201201929

      Thumbnail image of graphical abstract

      The study reveals that IgA antibodies directed against EGFR and engaging Fcalpha receptor (FcαRI) on effector cells, have in vivo anti-cancer activity. These data support the development of novel immunotherapeutic strategies based on targeting FcαRI.

    5. You have full text access to this OnlineOpen article
      Role of stress-inducible protein-1 in recruitment of bone marrow derived cells into the ischemic brains (pages 1227–1246)

      Shin-Da Lee, Ted Weita Lai, Shinn-Zong Lin, Chen-Huan Lin, Yung-Hsiang Hsu, Chi-Yuan Li, Hsiao-Jung Wang, Wei Lee, Ching-Yuan Su, Yung-Luen Yu and Woei-Cherng Shyu

      Article first published online: 8 JUL 2013 | DOI: 10.1002/emmm.201202258

      Thumbnail image of graphical abstract

      This work identifies HIF-1α-mediated transcription of STI-1 and PrPc interaction as leading to BMDCs recruitment into ischemic brains following stroke in both patients and animal models of stroke, highlighting novel neuroprotective possibilities.

    6. You have full text access to this OnlineOpen article
      Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance (pages 1247–1262)

      Irina Lonskaya, Michaeline L. Hebron, Nicole M. Desforges, Alexander Franjie and Charbel E.-H. Moussa

      Article first published online: 4 JUL 2013 | DOI: 10.1002/emmm.201302771

      Thumbnail image of graphical abstract

      Two FDA-approved tyrosine kinase inhibitor drugs, Bosutinib and Nilotinib, are shown to ameliorate Alzheimer's disease pathology in mouse models by increasing soluble parkin and leading to amyloid clearance and cognitive improvement.

    7. You have full text access to this OnlineOpen article
      The K+ channel GIRK2 is both necessary and sufficient for peripheral opioid-mediated analgesia (pages 1263–1277)

      Dinah Nockemann, Morgane Rouault, Dominika Labuz, Philip Hublitz, Kate McKnelly, Fernanda C. Reis, Christoph Stein and Paul A. Heppenstall

      Article first published online: 1 JUL 2013 | DOI: 10.1002/emmm.201201980

      Thumbnail image of graphical abstract

      GIRK channels are indispensable for peripheral opioid analgesia. The absence of GIRK channels from mouse dorsal root ganglion neurons questions the predictive validity of mice as a model organism for investigating peripheral GPCRmediated analgesia.

    8. You have full text access to this OnlineOpen article
      Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling (pages 1278–1295)

      Rune Busk Damgaard, Berthe Katrine Fiil, Carsten Speckmann, Monica Yabal, Udo zur Stadt, Simon Bekker-Jensen, Philipp J. Jost, Stephan Ehl, Niels Mailand and Mads Gyrd-Hansen

      Article first published online: 1 JUL 2013 | DOI: 10.1002/emmm.201303090

      Thumbnail image of graphical abstract

      The X-linked lymphoproliferative syndrome type-2 is an immunodeficiency disease caused by mutations in the XIAP gene. BIR2 domain mutations in patients impair RIPK2 binding and NOD2-dependent innate immune signaling, explaining some of the pathology.

  5. Masthead

    1. Top of page
    2. Closeups
    3. Perspectives
    4. Review
    5. Research Articles
    6. Masthead
    1. You have full text access to this OnlineOpen article
      Masthead (EMBO Mol. Med. 8/2013) (pages i–ii)

      Article first published online: 5 AUG 2013 | DOI: 10.1002/emmm.201370081

SEARCH

SEARCH BY CITATION